Salute e Benessere

Ketabon To Present Advancements In At-Home Ketamine Therapy For…

Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in Patients 37th European College of Neuropsychopharmacology (ECNP) Congress 2024 , taking place on September 21-24, 2024 in Milan. KET01 is an oral prolonged-release ketamine formulation developed for treatment-resistant depression (TRD). Topline results from the Phase 2 trial, published in August 2023 , demonstrated rapid improvement in...
Nasdaq GlobeNewswire
18/09/2024

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving…

New Biological Data Released from IRO® Cell Therapy Manufacturing Platform ® ( ee-RO ). In early 2024, Ori and Charles River collaborated through Ori's LightSpeed Early Access Program (LEAP), designed to provide access to the IRO platform for use in clinically relevant applications. During the collaboration, Ori and Charles River conducted head-to-head process runs comparing the IRO platform's biological performance to a process Charles River specifically optimized for CAR-T therapy over...
Nasdaq GlobeNewswire
18/09/2024

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for…

Our preliminary tabulation indicates the voting threshold has not been reached on Proposals 3 & 5. The proposed Merger cannot proceed unless holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 are voted FOR Proposals 3 & 5 (as described below). Our preliminary tabulation indicates the voting threshold has not been reached on Proposals 3 & 5. The proposed Merger cannot proceed unless holders of a majority of the voting power of Kintara's...
PR Newswire
18/09/2024

Venturi Cardiology and Caristo Diagnostics Introduce AI-Enabled Heart Disease…

OXFORD, England, Sept. 18, 2024 /PRNewswire/ -- Venturi Cardiology, a leading, state of the art cardiology clinic in North West England offering rapid access to clinical consultations and advanced diagnostics, has partnered with Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, to offer Caristo's AI-enabled CaRi-Heart® technology to patients in its growing practice. Venturi Cardiology is part of DHC Group, a portfolio of healthcare companies that…
PR Newswire
18/09/2024

Tilray Medical Launches Redecan Cannabis Brand in Australia

EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, said, “The launch of Redecan, a premium cannabis brand, in Australia is another significant milestone for Tilray Medical, as we relentlessly pursue our vision of making high-quality medical cannabis products accessible to patients worldwide. The launch of Redecan further expands our medical cannabis portfolios alongside...
Nasdaq GlobeNewswire
18/09/2024

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered…

Abstract Title Abstract Title Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer (NPC) patients Abstract No.: 899P The presentation highlights that the Phase I clinical trial of BRG01 has successfully completed dose-limiting toxicity (DLT) observations and efficacy evaluations in nine patients,all diagnosed with advanced NPC. Notably, 100% of participants had previously...
PR Newswire
18/09/2024

Thermo Compression Forming Market worth $13.37 billion by 2029 - Exclusive…

240 – Tables 59 – Figures 260 – Pages 240 – Tables59 – Figures260 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114021695 Thermoplastic Foams by type segment dominate the market by highest share of the thermo compression forming market during the forecasted period. Thermoplastic Foams are dominating because of their balanced mechanical qualities and excellent performance-to-cost ratios. These foams have many beneficial...
PR Newswire
18/09/2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at…

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms "We are excited to share results from our preclinical studies, which highlight the activity of ZW220 in models of non-small cell lung, ovarian, and uterine cancers, as well as ZW251 in hepatocellular carcinoma models, both of which leverage our novel proprietary payload, ZD06519," said Paul Moore, Ph.D., Chief Scientific…
Nasdaq GlobeNewswire
18/09/2024

Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of…

The advance purchase agreement (APA) will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.Availability of all 500,000 doses has been secured for 2024.COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024– Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN ®...
Nasdaq GlobeNewswire
18/09/2024

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of…

Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision for a longer, healthier life and the democratization of genomics to revolutionize the way we evade "avoidable disease" and stay healthy longer. The company is recognized as a leader in the rapidly expanding industry of longevity medicine due to its deep expertise in genomics and other fields of precision medicine such as imaging, and its unmatched, longitudinal patient…
PR Newswire
18/09/2024

Tetra Pharm Technologies Relocates to Copenhagen Towers

"Driven by our vision for innovation, we've chosen Copenhagen Towers as our new home. Its vibrant business ecosystem and exceptional amenities align perfectly with our mission", says Jesper Breum, COO, Tetra Pharm Technologies. "Driven by our vision for innovation, we've chosen Copenhagen Towers as our new home. Its vibrant business ecosystem and exceptional amenities align perfectly with our mission", saysJesper Breum, COO, Tetra Pharm Technologies. Copenhagen Towers…
PR Newswire
18/09/2024

Kitchen Sinks Market to Reach $5.4 Billion, Globally, by 2034 at 3.9% CAGR…

Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/A16899 Request The Sample PDF Of This Report:https://www.alliedmarketresearch.com/request-sample/A16899 Prime determinants of growth Increase in home renovation and remodeling activities, driven by consumer desire for modern and functional kitchen spaces, have boosted demand for innovative kitchen sink designs. The trend toward open and aesthetically pleasing kitchen layouts has led to...
PR Newswire
18/09/2024

Biocomposites acquires remaining shares in manufacturers of SYNICEMTM and…

KEELE, England, Sept. 18, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the acquisition of the remaining shares in Laboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. – gaining full control of the SYNICEMTM and Subiton product ranges. KEELE,England,Sept. 18, 2024/PRNewswire/ --Biocomposites, an...
PR Newswire
18/09/2024

Clarivate Announces 15th Annual Pharmavision India Conference Agenda

In a country with billions of people, addressing challenges such as healthcare affordability and access is crucial. Organizations must adopt effective, patient-centric approaches across diverse functions to ensure return on investment and a competitive advantage. As the healthcare landscape evolves, balancing these priorities is essential for sustainable growth and better patient outcomes. Pharmavision India 2024 will provide attendees with the opportunity to tackle the industry's most urgent…
PR Newswire
18/09/2024

Implantica announces excellent data from an independent study of 158 RefluxStop™…

This German study included 158 patients and reported impressive two-year follow-up effectiveness and safety outcomes with patients achieving significant improvement in their symptoms, and as a result, 96.4% of patients discontinued their regular PPI medication. An impressive 90.9% improvement in GERD-HRQL quality of life score was achieved although many of the patients had difficult-to-treat conditions, such as 22% had large hiatal hernia (over 3 cm), 44% active esophagitis and 10% precancerous…
PR Newswire
18/09/2024

Medvarsity Announces the AI Revolution in Healthcare Summit: The Largest AI in…

Gerald Jaideep, CEO of Medvarsity, emphasized the importance of the event, adding that, "AI is reshaping healthcare, from diagnostics to drug discovery. This event represents our commitment to bringing together visionary thinkers to explore the potential of AI in healthcare. Together, we can challenge existing approaches and reshape the future of patient care. AIRH Summit provides an opportunity for innovators to connect, exchange ideas, and drive change." Gerald Jaideep, CEO of…
PR Newswire
18/09/2024

One of Europe's largest port-infrastructure companies implements Aino Health's…

One of Europe's largest port-infrastructure companies implements Aino Health's SaaS-solution for 850 employees, to be socially sustainable and to strengthen their position as a productive, attractive and future-proof employer. One of Europe's largest port-infrastructure companies has chosen to implement Aino Health's SaaS-solution Health Manager. The agreement includes a total of 850 new subscriptions. The implementation of Aino has been initiated from the ambition to digitize all work...
Nasdaq GlobeNewswire
18/09/2024

Nicox Announces Approval of ZERVIATE in China

Press ReleaseNicox Announces Approval of ZERVIATE in China Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE ®for ocular itching in China ZERVIATE ®launch in China will add a further royalty revenue stream for NicoxSeptember 18, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Chinese...
Nasdaq GlobeNewswire
18/09/2024

Valneva Submits Label Extension Applications for its Chikungunya Vaccine…

To potentially include adolescents and antibody persistence up to two yearsSaint Herblain (France), September 18, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ ®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application...
Nasdaq GlobeNewswire
18/09/2024

CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel…

Key Takeaways from the CEACAM5 Market Report Key Takeaways from the CEACAM5 Market Report Discover which therapies are expected to grab the CEACAM5 drugs market share @CEACAM5 Drugs Market Report CEACAM5 Drugs Market Dynamics The CEACAM5 drugs market is rapidly evolving due to the molecule's significance in the treatment of various cancers, particularly colorectal, gastric, and non-small cell lung cancers. One of the primary drivers of the CEACAM5 drugs market is the...
PR Newswire
17/09/2024

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with…

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1 ,2 Kisqali ®(ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with...
Nasdaq GlobeNewswire
17/09/2024

EssilorLuxottica unveils plans for its new corporate headquarters in Paris

EssilorLuxottica unveils plans for its new corporate headquarters in ParisParis, France (September 17, 2024)– EssilorLuxottica announced today the signing of a long-term pre-letting agreement for its new global headquarters in Paris, expected to open late 2027. Located at Place Valhubert, in the heart of the lively Austerlitz district -Paris 13e-, boasting a tech startup and global digital company scene, the new headquarters will bring together in a single building up to more than...
Nasdaq GlobeNewswire
17/09/2024

Moose Knuckles Unveils Full Fall/Winter 2024 Collection, Featuring Dennis…

Campaign Highlights: Campaign Highlights: FromCarlos Nazario, Global Artistic Director:"The complete Fall/Winter 2024 collection represents the culmination of our vision for Moose Knuckles – a perfect blend of sophistication, functionality, and bold style. Working withDennis Rodmanhas been incredible; his fearless approach to fashion and life embodies everything the brand stands for. Paired with Amelia's return, we're showcasing the versatility and appeal of Moose Knuckles to a...
PR Newswire
17/09/2024

Idorsia continues to further the science of sleep and insomnia with new…

Allschwil, Switzerland – September 17, 2024Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with chronic insomnia, will be presented at Sleep Europe 2024 – the 27th Congress of the European Sleep Research Society (ESRS), taking place in Seville, Spain, September 24–27, 2024.The following posters will be presented: Lederer K, et al. Efficacy and safety of daridorexant in patients...
Nasdaq GlobeNewswire
17/09/2024
Altri  Comunicati